Corcept Q4 revenue $135.4M (+31% YoY); reiterates FY2024 guidance $600-630M

CORCEPT THERAPEUTICS INC

2023-FY EPS reported $0.94 revenue$482,375,000

Q4 revenue $135.4M (+31% YoY); net income $31.4M ($0.28 diluted EPS) vs $16.6M in Q4 2022.
Full-year 2023 revenue $482.4M (+20% YoY); net income $106.1M ($0.94 diluted EPS).
Cash and investments $425.4M; 2024 revenue guidance reiterated at $600-$630M.
NDA for relacorilant in Cushing's expected Q2 2024; GRACE results Q2; CATALYST shows 24% hypercortisolism prevalence in first 700 patients.
ROSELLA ovarian cancer trial and DAZALS ALS trial results expected by year-end 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CORCEPT THERAPEUTICS INC reported the quarter and year ended December 31, 2023 results: revenue $135.4 million, net income $31.4 million, EPS $0.28. Guidance reaffirmed.

Period: the quarter and year ended December 31, 2023
Revenue: $135.4 million
Net income: $31.4 million
EPS: $0.28
Guidance: reaffirmed
Result: reported results

Exact text from the filing

today reported its results for the quarter and year ended December 31, 2023. Financial Results • Fourth quarter revenue of $135.4 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CORCEPT THERAPEUTICS INC reported the year ended December 31, 2023 results: revenue $482.4 million, net income $106.1 million, EPS $0.94. Guidance reaffirmed.

Period: the year ended December 31, 2023
Revenue: $482.4 million
Net income: $106.1 million
EPS: $0.94
Guidance: reaffirmed
Result: reported results

Exact text from the filing

and year ended December 31, 2023. Financial Results • Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022 • Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022 • Reiterated 2024 revenue guidance of $600 – $630 million • Fourth quarter net income of $31.4 million, compared to $16.6 million in fourth

View on SEC.gov

Browse all earnings releases →

CORCEPT THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001628280-24-005048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.